| Title |
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
|
|---|---|
| Published in |
Current Rheumatology Reports, August 2018
|
| DOI | 10.1007/s11926-018-0769-6 |
| Pubmed ID | |
| Authors |
Sizheng Zhao, Laura Chadwick, Eduardo Mysler, Robert J. Moots |
| Abstract |
Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of biosimilar trial data. Currently, three adalimumab biosimilars are approved in Europe and/or the USA: Amgen's ABP 501 (AMJEVITA/Solymbic), Boehringer Ingelheim's BI 695501 (Cyltezo) and Samsung Bioepis's SB5 (Imraldi). All three agents met their pre-specified equivalence criteria. Subtle differences in adverse events and clinical responses between the reference and biosimilar products were noted. The introduction of adalimumab biosimilars will offer exciting opportunities in improving treatment access and increasing treatment options for RA and other licensed indications. Real-world data will further provide assurances on efficacy as well as safety. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 4 | 36% |
| Brazil | 1 | 9% |
| Spain | 1 | 9% |
| India | 1 | 9% |
| Unknown | 4 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 73% |
| Practitioners (doctors, other healthcare professionals) | 2 | 18% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 94 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 18% |
| Student > Master | 13 | 14% |
| Other | 8 | 9% |
| Student > Bachelor | 6 | 6% |
| Student > Ph. D. Student | 4 | 4% |
| Other | 8 | 9% |
| Unknown | 38 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 14% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Agricultural and Biological Sciences | 4 | 4% |
| Chemistry | 3 | 3% |
| Other | 8 | 9% |
| Unknown | 41 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 126. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2023.
All research outputs
#296,007
of 23,752,589 outputs
Outputs from Current Rheumatology Reports
#8
of 722 outputs
Outputs of similar age
#6,826
of 332,416 outputs
Outputs of similar age from Current Rheumatology Reports
#1
of 17 outputs
Altmetric has tracked 23,752,589 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 722 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,416 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.